Sign In
Buy RPRX
$53.57
+0.610 (+1.15%)
At Close: Jun 22, 2026
NASDAQ Stocks Hitting New 52-Week Lows: 4 Stocks To Watch
05:38pm, Monday, 26'th Jun 2023
While a very few are just now coming off of all-time highs (Nvidia, among others), some are recently all the way down to new 52-week lows.
Royalty Pharma: A Strong Start To 2023 Bodes Well For The Future
11:35am, Saturday, 10'th Jun 2023
Royalty Pharma acquires royalties on drugs in the commercial phase and the development phase. Thanks to a milestone payment, this year's cash receipts will come in close to $3B. The annualized free ca
Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
08:15am, Wednesday, 07'th Jun 2023
NEW YORK, June 07, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13,
Insider Buying: CEO Pablo Legorreta Acquires 150,000 Shares of Royalty Pharma PLC (RPRX)
06:06pm, Thursday, 25'th May 2023
On May 24, 2023, Pablo Legorreta, CEO, Chairman of the Board, and 10% Owner of Royalty Pharma PLC ( RPRX , Financial), purchased 150,000 shares of the company. This move is significant as it demonstra
Royalty Pharma (RPRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
12:13pm, Tuesday, 09'th May 2023
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street e
Should You Buy Royalty Pharma (RPRX) Ahead of Earnings?
09:54am, Monday, 08'th May 2023
Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference
04:15pm, Wednesday, 03'rd May 2023
NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 20
Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023
09:01am, Thursday, 13'th Apr 2023
NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023 before the U.S. fina
GBOOY vs. RPRX: Which Stock Is the Better Value Option?
01:00pm, Tuesday, 21'st Mar 2023
GBOOY vs. RPRX: Which Stock Is the Better Value Option?
Royalty Pharma raises FY2023 guidance after $475M Pfizer milestone payment
11:42am, Wednesday, 15'th Mar 2023
Royalty Pharma plc announced that it is raising its full year 2023 Adjusted Cash Receipts (non-GAAP) guidance to between $2.85 billion and $2.95 billion, up from $2.375 billion and $2.475 billion pre
GBOOY or RPRX: Which Is the Better Value Stock Right Now?
12:47pm, Thursday, 02'nd Mar 2023
GBOOY vs. RPRX: Which Stock Is the Better Value Option?
Royalty Pharma plc (RPRX) Q4 2022 Earnings Call Transcript
01:49pm, Wednesday, 15'th Feb 2023
Royalty Pharma plc (NASDAQ:RPRX ) Q4 2022 Earnings Conference Call February 15, 2023 8:00 AM ET Company Participants George Grofik - Senior Vice President, Head of Investor Relations & Communications
Royalty Pharma (RPRX) Matches Q4 Earnings Estimates
09:47am, Wednesday, 15'th Feb 2023
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 0% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Royalty Pharma to Present at Upcoming Investor Conferences
04:15pm, Thursday, 09'th Feb 2023
NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the months of February and
Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?
01:32pm, Wednesday, 01'st Feb 2023
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
